The US District Court for the Southern District of New York has upheld the contention of Teva Pharmaceuticals that NATCO Pharma’s abbreviated new drug application (ANDA) for the generic version of Copaxone infringes all the asserted claims of Teva Pharmaceuticals.
Earlier in June 2008, Natco has filed, with its partner Mylan Inc. an ANDA seeking approval for marketing of the generic version of the relapsing, remitting multiple sclerosis drug Copaxone and obtained a Para IV certification which essentially challenges the existing patents held by Teva Pharmaceuticals.
Natco is disappointed with the Court’s decision. While the company has not yet had the opportunity to review the Court’s opinion, it will fully investigate all available options for appeal once the Court's full opinion becomes available.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. The company began its operations in 1984 in Andhra Pradesh.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: